Auro Laboratories Ltd. (BSE: 530233) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹145 Cr, it ranks #2,927 by market cap among the 6,197 Indian listed companies on FinBizNet, and #61 of 86 in Medicinal Chemicals and Botanical Products. At ₹234.50 (as of 16 Nov 2026), the share price is 26.0% below its 52-week high of ₹317.00 and 17.3% above its 52-week low of ₹199.95. The share price is up 25.4% over one year and down 2.4% over three months.
| Current Price | ₹234.50 |
|---|---|
| Market Cap | ₹145 Cr |
| BSE Code | 530233 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 41.2 |
| Return on Equity | 7.91% |
| Return on Assets | 4.20% |
| 52-Week Range | ₹199.95 – ₹317.00 |
| 1-Year Price Change | +25.4% |
| 3-Month Price Change | -2.4% |
| Beta (1Y) | 0.24 |
| Headquarters | Mumbai, Maharashtra |
| Website | www.aurolabs.com |
Delivery averaged 74.0% of traded volume across 15 BSE sessions (21 Oct 2026 – 13 Nov 2026).
Auro Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and generic formulations in India. It offers antihistamine; muscle relaxant; diuretic; iron deficiency; anti-diabetic, including Metformin HCL; anti-fungal, ulcer, malaria, and inflammatory; iodine supplement; analgesics; antacids; potassium and sodium iodide; and microcrystalline cellulose. The company also provides specialty chemicals comprising guanidine nitrate; dimethyl amine HCl; 2-ethoxy benzoic acid; and 3,4,5 - trimethoxy benzoic acid. In addition, it offers intermediates consisting of glibenclamde sulphonamide for use in API glibenclamide; cis-bramo benzoate and cls-tosylate that are used in API Ketoconazol; 3,4,5 - trimethoxy benzoic acid; 2-ethoxy benzoic acid for use in API sildenafil citrate; and 5-bromo phthalide that is used in API citalopram. It also exports products to Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain, and the United Kingdom. The co
1. Pharmaceuticals-This segment manufactures and sells generic active pharmaceutical ingredients.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Auro Laboratories Ltd. | ₹145 Cr | 41.2 | 7.91% | — | +25.4% |
Listed by market capitalisation. Ratios are shown for context only.
Auro Laboratories Ltd. is trading at ₹234.50, with a market capitalisation of ₹145 Cr.
Auro Laboratories Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Auro Laboratories Ltd. has a P/E of 41.2 and a return on equity of 7.91%.
Auro Laboratories Ltd. is listed on the BSE under the scrip code 530233.
Auro Laboratories Ltd.'s share price is up 25.4% over one year and down 2.4% over three months. Its 52-week range is ₹199.95 to ₹317.00.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.